GRADUAL-3 is a 24-week maintenance study from Gan & Lee Pharmaceuticals. People who had already taken bofanglutide every two weeks for 52 weeks were randomized to monthly bofanglutide (24 mg or 48 mg) or monthly placebo. In a November 4, 2026 topline release, the company reported weight changes of 0.41% and -0.12% on monthly drug versus 8.52% on placebo. The study tested weight maintenance after a year of treatment, and the full data have not been published.
Ask PeptideBlog about any peptide
Research snapshot
| Category | Current information |
|---|---|
| Compound | Bofanglutide (also coded GZR18), a long-acting GLP-1 receptor agonist from Gan & Lee Pharmaceuticals |
| Study | GRADUAL-3, described by the sponsor as a phase IIIb maintenance study built on GRADUAL-1 |
| Design | Randomized, placebo-controlled, 24 weeks, after 52 weeks of bofanglutide every two weeks |
| Population | Chinese adults with overweight or obesity who completed the 52-week lead-in and met eligibility criteria |
| Groups | Bofanglutide 24 mg monthly, bofanglutide 48 mg monthly, placebo monthly |
| Primary endpoint | Percent change in body weight from baseline after 24 weeks |
| Evidence level | Sponsor-reported topline press release, Nov 4, 2026. Not peer reviewed. No full dataset. |
| Status of the drug | Investigational. A July 2026 paper lists it among drugs in phase III trials, and the November release announces no approval. |
What the company reported
The primary source is Gan & Lee’s November 4, 2026 release. It reports one primary result.
| Group | Monthly dose | Mean change in body weight over 24 weeks, as printed |
|---|---|---|
| Bofanglutide | 24 mg | 0.41% |
| Bofanglutide | 48 mg | -0.12% |
| Placebo | none | 8.52% |
The company gives a p value below 0.0001 for both comparisons with placebo. It also says waist circumference, blood pressure and lipid levels were held, that the most common adverse events were gastrointestinal and mostly mild to moderate, and that no new safety signal appeared. It does not give group sizes, how many people finished, absolute weights, or any adverse event rates.
Two details of the table need care. The release prints no plus sign on 0.41% or 8.52%. Read against the company’s own point that monthly dosing prevents regain, they are weight gains, so the monthly groups roughly held their weight and the placebo group put on a little under nine percent. The release also says “from baseline” without defining it. It almost certainly means the start of the maintenance phase, because an 8.52% gain above the original pre-treatment weight after a year of treatment would be hard to square with the rest of the report. Treat both readings as inferences until the full paper appears.
Doses and schedules reported
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Setting | Amount | Frequency | Duration | Evidence category |
|---|---|---|---|---|
| GRADUAL-3 maintenance | 24 mg or 48 mg | Once monthly | 24 weeks | Company-reported human trial (topline release) |
| Registry requirement for entry into the maintenance study | Last dose of 24 mg or more | Every two weeks lead-in | 52 weeks lead-in | Registered human trial |
| Phase 2b obesity trial | 12, 18, 24 or 48 mg | Every two weeks (and 24 mg weekly) | 30 weeks | Published human clinical trial, PMID 41760612 |
No dose of bofanglutide has been established as safe or effective for any use, and no source reviewed describes a gray-market dosing culture for it. These rows record what trials administered.
How the study was built
Participants first took bofanglutide every two weeks for 52 weeks in GRADUAL-1. Those who completed that lead-in and met the eligibility criteria were randomized, according to their last dose of 24 mg or 48 mg, to bofanglutide or placebo once a month for 24 weeks. The per-injection amount therefore appears to have stayed the same while the interval doubled, though the release does not say that in so many words.
The registry record that matches this design is NCT07292441, titled as an extension of the phase 3 weight-loss study (acronym GZR18-BWM-303), with 500 participants planned and a start date of January 22, 2026. The registry never uses the name GRADUAL-3, so the link between the two is a design match and not a confirmed identity. Its eligibility rules are informative: participants needed a last dose of at least 24 mg, could not have diabetes, and could not have used semaglutide (Wegovy) in the original study. The registry also lists safety measures the release does not mention, including lipase, amylase, calcitonin, depression scores and anti-drug antibodies, so those are the numbers to look for in the full report.
The registry lists primary completion as September 2027 and shows sites in Beijing only. Whether that is out of date or reflects a different analysis is not stated.

Maintenance is a different question from weight loss
GRADUAL-3 did not randomize anyone to start treatment on a monthly schedule. Everyone had already spent a year on a more intensive regimen, and the question was whether a lighter schedule could hold the result. That is useful, but it says nothing yet about how much weight a person loses when monthly dosing is used from the start, and it does not show that one monthly shot matches the weight loss of the weekly drugs.
The population matters too. People who finished 52 weeks, tolerated a last dose of 24 mg or more and had no diabetes are a filtered group. Anyone who dropped out, could not tolerate high doses or developed diabetes is not in the maintenance comparison.

How it sits next to other maintenance trials
Withdrawal and maintenance designs exist for the better-known weekly drugs. The table below places them side by side, with one warning: they used different drugs, lead-in lengths, reference points and populations, so the numbers cannot be ranked against each other or against GRADUAL-3.
| Trial | Drug | Lead-in | Randomized phase | Result in the placebo arm | Reference point | Source |
|---|---|---|---|---|---|---|
| STEP 4 | Semaglutide 2.4 mg weekly | 20 weeks, mean loss 10.6% | 48 weeks, 803 randomized | +6.9% (continued drug: -7.9%) | Week 20 | JAMA 2021, PMID 33755728 |
| SURMOUNT-4 | Tirzepatide 10 or 15 mg weekly | 36 weeks, mean loss 20.9% | 52 weeks, 670 randomized | +14.0% (continued drug: -5.5%) | Week 36 | JAMA 2024, PMID 38078870 |
| SURMOUNT-MAINTAIN | Tirzepatide, continued, reduced to 5 mg, or placebo | 60 weeks open label | 52 weeks, 378 randomized | -9.9% from original baseline (continued: -21.9%, 5 mg: -16.6%) | Original baseline, week 112 | Lancet 2026, PMID 42119587 |
| GRADUAL-3 | Bofanglutide monthly 24 or 48 mg | 52 weeks every two weeks | 24 weeks, group sizes not reported | 8.52% (monthly drug: 0.41% and -0.12%) | Not defined in the release | Sponsor release, Nov 4, 2026 |
Three things stand out. First, reference points differ, so a placebo arm “regaining 14%” and one “ending 9.9% below baseline” can describe similar situations. Second, SURMOUNT-MAINTAIN tested a lower dose and GRADUAL-3 tested a lower frequency, which are different ways of asking whether less drug can hold the loss. Third, the populations differ: GRADUAL-3 enrolled Chinese adults, and the bofanglutide phase 2b cohort averaged 33.1 years old, so age and body-size profiles may differ from those in the Western trials (each paper reports its own).
The company calls GRADUAL-3 the first completed phase IIIb study of its kind to test once-monthly maintenance in a randomized design. That is the sponsor’s claim. Viking Therapeutics reported a shorter, earlier-phase study with monthly maintenance arms in September 2026, which is covered on the VK2735 entry.
What bofanglutide is
| Technical property | Information |
|---|---|
| Primary name | Bofanglutide |
| Alternative names | GZR18 |
| Peptide class | Long-acting GLP-1 receptor agonist (analog) |
| Primary biological target | GLP-1 receptor |
| Sequence, molecular formula, CAS | Not reliably established (no verified source found) |
| Developer | Gan & Lee Pharmaceuticals |
| Development status | Investigational |
Bofanglutide, coded GZR18, is a long-acting analog of GLP-1, the gut hormone that signals fullness and slows stomach emptying. It acts on the GLP-1 receptor alone, unlike tirzepatide (GIP and GLP-1) or retatrutide (GIP, GLP-1 and glucagon). A 2022 laboratory and animal paper reported albumin binding and receptor activity similar to semaglutide and liraglutide (PMID 35718129). The sources reviewed for this article give no verified sequence, molecular formula or CAS number, so none are listed.
Its main human weight data come from a phase 2b trial of 340 Chinese adults with overweight or obesity, published February 27, 2026 in Signal Transduction and Targeted Therapy. Mean weight change at week 30 ranged from -9.75% to -16.69% across bofanglutide groups, against -1.15% on placebo. About 84% of bofanglutide recipients had gastrointestinal events, against about 33% on placebo, mostly grade 1 or 2. Those figures belong to that earlier trial and cannot be carried over to GRADUAL-3, whose release gives no rates.
Registered phase 3 work includes a placebo-controlled study in China (NCT06728124, 630 planned) and an open-label comparison with Wegovy (NCT07150975, 420 planned, primary completion listed as June 2027).
Safety and what is still missing
The release says no new safety signal appeared and that gastrointestinal events dominated. That is all it says. Missing from the public record: how many people were randomized to each arm, how many finished, adverse event and discontinuation rates, serious adverse events, immune response to the drug, and any absolute weights or lead-in weight loss. Without lead-in weight loss, 0.41% cannot be put in proportion.
The usual cautions apply. The report comes from the sponsor. It describes a topline result, not a peer-reviewed paper. Only completers of the lead-in were eligible. The trial ran 24 weeks, which says little about durability. The population was Chinese adults, so generalizability to other groups is unknown. The comparison arm was placebo, so the study says nothing about how monthly bofanglutide compares with weekly semaglutide or tirzepatide.
Why monthly maintenance matters scientifically
Weight regain after stopping is well documented, and the open question for every obesity drug is how little exposure is enough to hold the result. Lower dose (SURMOUNT-MAINTAIN) and longer intervals (GRADUAL-3) are two routes to that answer. If a monthly step holds weight in a full, peer-reviewed dataset, it would also mean half as many injections for a long-term phase. For now that remains a company finding. Regain trials for other drugs are summarized at The Weight Loss Atlas.
What to watch next
- Full GRADUAL-3 data, which the company says will go to future conferences and peer-reviewed journals.
- Updates to NCT07292441 (dates, sites, results).
- The registry’s open-label head-to-head with Wegovy, NCT07150975, which is the study that could support any comparison.
- Latin American phase 3 trials versus semaglutide, NCT07622810 and NCT07628985, both listed as not yet recruiting.
- Other once-monthly programs on this site: VESPER-SWITCH (monthly weight maintenance) and ASC37.
Frequently asked questions
What is GRADUAL-3? A 24-week randomized maintenance study from Gan & Lee Pharmaceuticals, run in people who had taken bofanglutide every two weeks for 52 weeks, comparing monthly bofanglutide with monthly placebo.
Did monthly bofanglutide cause weight loss in GRADUAL-3? The study was not built to test that. Participants had a year of treatment first. The 48 mg monthly group changed by -0.12% and the 24 mg group by 0.41%, as printed in the release.
How much weight did the placebo group regain? The release reports 8.52% over 24 weeks. Group size, lead-in weight loss and the exact reference point are not given.
What doses were used? 24 mg and 48 mg monthly in GRADUAL-3. The earlier phase 2b trial used 12, 18, 24 and 48 mg every two weeks and 24 mg weekly. These are amounts trials administered, not advice.
Is the result peer reviewed? No. It is a topline press release dated November 4, 2026. The company plans conference and journal reports.
Is bofanglutide approved? The release announces no approval, and a July 2026 paper lists it among investigational drugs in phase III trials. Check the relevant regulator for current status.
How does it compare with tirzepatide or semaglutide? No head-to-head results exist. A comparison with Wegovy is registered (NCT07150975). Cross-trial comparisons are not valid, as the table above shows.
Who was in the study? Chinese adults with overweight or obesity who completed the lead-in. The registry also requires a last dose of 24 mg or more and excludes diabetes.
Bottom line
GRADUAL-3 is interesting because it asks a practical question: can a once-monthly step hold weight after a year of every-two-week treatment? The sponsor says yes, with the monthly groups reporting changes near zero and placebo 8.52%. That is a topline press release with no group sizes, no absolute weights and no safety rates, so it is a signal and not a settled result. The dosing information that is genuinely published is the phase 2b trial and the registry; the maintenance doses (24 mg and 48 mg monthly) come from the company release. Whether monthly dosing works from the start of treatment, matches weekly drugs or lasts beyond 24 weeks is not addressed. Status: investigational.
Sources
| Source | Organization | Date | Category |
|---|---|---|---|
| GRADUAL-3 topline release | Gan & Lee Pharmaceuticals | 2026-11-04 | Sponsor press release |
| NCT07292441 extension study record | ClinicalTrials.gov | Registry record | Clinical registry |
| NCT06728124, NCT07150975, NCT07622810, NCT07628985 | ClinicalTrials.gov | Registry records | Clinical registry |
| Bofanglutide phase 2b in Chinese adults with overweight or obesity (PMID 41760612) | Signal Transduct Target Ther | 2026-02-27 | Peer-reviewed trial |
| GZR18 preclinical pharmacology (PMID 35718129) | Eur J Pharmacol | 2022-06-16 | Peer-reviewed preclinical |
| Multiplexed LC-HRMS method listing nine GLP-1 agonists (PMID 42603384) | J Chromatogr A | 2026-07-21 | Peer-reviewed analytical paper (status description only) |
| STEP 4 (PMID 33755728) | Rubino et al., JAMA | 2021-04-13 | Peer-reviewed trial |
| SURMOUNT-4 (PMID 38078870) | Aronne et al., JAMA | 2024-01-02 | Peer-reviewed trial |
| SURMOUNT-MAINTAIN (PMID 42119587) | Horn et al., Lancet | 2026-05-12 | Peer-reviewed trial, sponsor funded |
More in the obesity peptides hub, or compare peptides side by side.